News release

City of Mississauga Thrilled with $200 Million Investment to Expand Resilience Biotechnologies Inc.’s Vaccine Manufacturing in Mississauga

Business and innovation | May 19, 2021

Yesterday, the Government of Canada announced a $200 million investment in Resilience Biotechnologies Inc., a Mississauga-based biomanufacturing facility, to help expand made-in-Canada vaccine solutions. With this investment, the Mississauga facility is expected to manufacture approximately 112 to 640 million doses of mRNA (messenger ribonucleic acid) vaccines per year.

“Investing in vaccine manufacturing is more important now than ever and I’m thankful that the federal government chose to invest in a Mississauga-based facility,” says Mayor Bonnie Crombie. “This investment is evidence that Mississauga is a leading national science hub that supports business development and growth. Through our relationships with biomanufacturing companies, like Resilience Biotechnologies Inc., we can continue to support growth and expansion in this sector.”

As part of this investment, Resilience Biotechnologies Inc. will expand their existing facility by adding 35,000 sq. ft. of space to create more capacity to manufacture vaccines and other biologics. This investment supports a larger, $400 million project that aims to develop Canada’s emergency preparedness for future pandemics.

“We are proud that Mississauga’s life sciences sector is making great contributions to Canada’s biomanufacturing capabilities that will support our national life sciences priorities for decades to come,” said Harold Dremin, Acting Director, Economic Development Office. “It’s exciting to know that a Mississauga-based company is the first in Canada to have both the capacity and capability to use leading-edge mRNA technologies to produce vaccines, and has the potential to develop future therapeutics for other diseases and chronic illnesses.”

Mississauga has the second-largest life sciences sector in Canada by employment, with more than 470 companies employing more than 25,000 people.


About Resilience Biotechnologies Inc.
Resilience Biotechnologies Inc. is located in Mississauga. It specializes in the development and manufacturing of clinical and commercial drugs, like vaccines. With this investment, Resilience Biotechnologies Inc. hopes to create and maintain 500 full-time jobs in Canada and create 50 co-op positions.

About Life Sciences in Mississauga
Mississauga is a connected ecosystem that cultivates and nurtures commercialization of life sciences innovations: a proven destination where diverse companies and exceptional talent grow, succeed and prosper. To learn more about advancements in Mississauga’s life sciences sector, visit


Media Contact:
City of Mississauga Media Relations
905-615-3200, ext. 5232
TTY: 905-896-5151